Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 28 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 7 7 28 versus TAYTULLA.
ORTHO-NOVUM 7/7/7-28 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits gonadotropin secretion, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 placebo tablets). Each active tablet contains 0.035 mg ethinyl estradiol and varying progestin doses: 7 tablets of 0.5 mg norethindrone, 7 tablets of 0.75 mg norethindrone, and 7 tablets of 1 mg norethindrone.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
EE: terminal half-life 13-27 hours (mean ~17 hours); NET: 7-13 hours (mean ~10 hours). Clinical context: steady state reached after 4-7 days; missed pills may reduce contraceptive efficacy.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Ethinyl estradiol (EE) is excreted in urine (40%) and feces (60%) as glucuronide and sulfate conjugates. Norethindrone (NET) is excreted primarily in urine (60-80%) as glucuronide conjugates, with 10% in feces. Biliary excretion contributes minimally.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive